Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status.

ABSTRACT:

Background

Modern therapeutic strategies have significantly improved the prognosis of advanced melanoma patients. Predictive factors of therapy response include serum LDH; however, predictive markers for long-term survival are currently largely lacking.

Patients and methods

Patients diagnosed with stage IV melanoma (AJCCv8) of cutaneous origin or unknown primary were identified from the prospective multicenter German Dermatologic Cooperative Oncology Group (DeCOG) skin cancer registry ADOREG. Baseline characteristics were compared between patient groups with short-term versus long-term survival. Statistical analysis included ROC analysis and multinomial regression analysis.

Results

Of 3066 stage IV melanoma patients entered into the ADOREG between 05/2014 and 06/2021,

SUBMITTER: Placke JM 

PROVIDER: S-EPMC11868123 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature